Back to resultsCLINICAL EVALUATION OF THE EFFICACY OF AN INTRA ORAL SPRAY FOR PATIENTS WITH XEROSTOMIA
Primary Purpose
Dry Mouth, Xerostomia.Hyaluronic Acid, Xylitol
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Lubricity
Sponsored by
About this trial
This is an interventional treatment trial for Dry Mouth, Xerostomia.Hyaluronic Acid, Xylitol
Eligibility Criteria
Inclusion Criteria:
- Have provided written informed consent prior to being entered into the study.
- Must be at least 18 years of age, male or female.
- Have at least 12 natural or restored teeth.
- Have a negative history of radiation therapy to head and neck
- Have a complaint of xerostomia
- Have an unstimulated salivary flow rate <0.25ml/minute which represents 35-50% of normal salivary function
- Agree not to have a dental prophylaxis or any other elective, non-emergency dental procedures (other than those provided during the study) any time during the study.
- Agree to abstain from the use of any products for xerostomia other than those provided in the study.
- Agree to comply with the conditions and schedule of the study.
Exclusion Criteria:
- Physical limitations or restrictions that might preclude normal tooth brushing.
- Evidence of gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or soft or hard tissue tumor of the oral cavity.
- Presence of severe gingivitis with 30 or more sites showing bleeding on probing.
- Evidence of major oral hard or soft tissue lesions or trauma at the baseline visit as determined by the Investigator/Examiner.
- Chronic disease with concomitant oral manifestations other than xerostomia
- Conditions requiring antibiotic treatment prior to dental prophylaxis and invasive procedures, such as heart murmur, history of rheumatic fever, valvular disease or certain prosthetic implants.
- History of uncontrolled diabetes or hepatic or renal disease, or other serious conditions or transmittable diseases, (e.g. cardiovascular disease, AIDS).
- Subjects who are currently undergoing, or require, extensive dental work or orthodontic treatment.
- Currently using bleaching trays.
- History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth sprays.
- Subjects who are nursing, pregnant or plan to become pregnant for the duration of the study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
HA formulation Oral Spray
Placebo Oral Spray
Arm Description
The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
Outcomes
Primary Outcome Measures
Relief from dry mouth using VAS scoring
At end of each treatment week they will be asked to answer the following VAS question
How well did this product make your mouth feel moist? At end of each treatment week they will be asked to answer the following VAS question
At the end of the study they will be asked: How would you rate the second mouthspray compared to the first Study mouthspray in terms of your mouth feeling moist?
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04719091
Brief Title
CLINICAL EVALUATION OF THE EFFICACY OF AN INTRA ORAL SPRAY FOR PATIENTS WITH XEROSTOMIA
Official Title
CLINICAL EVALUATION OF THE EFFICACY OF AN INTRA ORAL SPRAY FOR PATIENTS WITH XEROSTOMIA
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
January 2, 2016 (Actual)
Primary Completion Date
February 1, 2016 (Actual)
Study Completion Date
February 29, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
You First Services
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This cross-over group, double-blind, randomized, single center, study will enroll 26 subjects to target at least 24 subjects completing the study.Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of mouth spray. They will then be given their assigned product to use twice daily for one week. Subjects will maintain a daily diary of their use of the mouth spray and any oral effects they experience, and will answer all diary questions. Compliance will be assessed by subject diary and measurement of remaining test mouth spray in bottle when unused portion is returned to the clinic. Subjects will also receive 2 questionnaires to complete during the office visit at the end of each 7-day study period. After a 1 week washout, subjects will return to the office to begin the second period of the study, using the same study procedures and be assigned the alternate treatment mouth spray.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Mouth, Xerostomia.Hyaluronic Acid, Xylitol
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Triple(Participant, Care provider, investigator)
Allocation
Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HA formulation Oral Spray
Arm Type
Experimental
Arm Description
The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of Experimental mouth spray. They will then be given their assigned product to use twice daily for one week
Arm Title
Placebo Oral Spray
Arm Type
Placebo Comparator
Arm Description
The Study Examiner and staff will screen for subjects that meet the enrollment criteria. Subjects will be randomly assigned to one of two treatment groups. Oral soft and hard tissue examinations will be conducted at each visit. Following an initial 3-5 minute evaluation of resting salivary flow, subjects will wait 10 minutes and then use their assigned spray. They will then swallow, and unstimulated saliva will be collected for 3-5 minutes. They will then remain in the study center for 60 min to evaluate xerostomia relief by questionnaire at 5, 15, 30, 45 and 60 min. after the use of placebo mouth spray. They will then be given their assigned product to use twice daily for one week
Intervention Type
Device
Intervention Name(s)
Lubricity
Intervention Description
Oral spray
Primary Outcome Measure Information:
Title
Relief from dry mouth using VAS scoring
Description
At end of each treatment week they will be asked to answer the following VAS question
How well did this product make your mouth feel moist? At end of each treatment week they will be asked to answer the following VAS question
At the end of the study they will be asked: How would you rate the second mouthspray compared to the first Study mouthspray in terms of your mouth feeling moist?
Time Frame
3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have provided written informed consent prior to being entered into the study.
Must be at least 18 years of age, male or female.
Have at least 12 natural or restored teeth.
Have a negative history of radiation therapy to head and neck
Have a complaint of xerostomia
Have an unstimulated salivary flow rate <0.25ml/minute which represents 35-50% of normal salivary function
Agree not to have a dental prophylaxis or any other elective, non-emergency dental procedures (other than those provided during the study) any time during the study.
Agree to abstain from the use of any products for xerostomia other than those provided in the study.
Agree to comply with the conditions and schedule of the study.
Exclusion Criteria:
Physical limitations or restrictions that might preclude normal tooth brushing.
Evidence of gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque or soft or hard tissue tumor of the oral cavity.
Presence of severe gingivitis with 30 or more sites showing bleeding on probing.
Evidence of major oral hard or soft tissue lesions or trauma at the baseline visit as determined by the Investigator/Examiner.
Chronic disease with concomitant oral manifestations other than xerostomia
Conditions requiring antibiotic treatment prior to dental prophylaxis and invasive procedures, such as heart murmur, history of rheumatic fever, valvular disease or certain prosthetic implants.
History of uncontrolled diabetes or hepatic or renal disease, or other serious conditions or transmittable diseases, (e.g. cardiovascular disease, AIDS).
Subjects who are currently undergoing, or require, extensive dental work or orthodontic treatment.
Currently using bleaching trays.
History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth sprays.
Subjects who are nursing, pregnant or plan to become pregnant for the duration of the study.
12. IPD Sharing Statement
Learn more about this trial
CLINICAL EVALUATION OF THE EFFICACY OF AN INTRA ORAL SPRAY FOR PATIENTS WITH XEROSTOMIA
We'll reach out to this number within 24 hrs